Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Immutep Ltd ADR (IMMP)

Immutep Ltd ADR (IMMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immutep Completes FDA Project Optimus, Advances Efti Trials Tipranks - Wed Oct 15, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Immutep (...

IMMP : 0.4424 (+4.98%)
Immutep Announces Favorable Safety Profile for First-in-Class LAG-3 Agonist IMP761 in Phase I Trial Quiver Quantitative, Inc. - Tue Dec 17, 2024

Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025.Quiver AI SummaryImmutep Limited has released promising initial safety...

IMMP : 0.4424 (+4.98%)
Immutep Reports Promising Clinical Results for Efti in Combination with Pembrolizumab in Patients with Difficult-to-Treat Head and Neck Cancer Quiver Quantitative, Inc. - Thu Dec 12, 2024

Immutep reports promising clinical results for efti combined with pembrolizumab in treating difficult head and neck cancer patients.Quiver AI SummaryImmutep Limited has announced promising clinical results...

IMMP : 0.4424 (+4.98%)

Barchart Exclusives

The 3 Best Buy-and-Hold Dividend Stocks to Load Up on for Lifetime Income Barchart - Mon Jul 6, 6:30PM CDT
These three dividend stalwarts have rewarded shareholders with decades of steadily rising income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.